Interv Akut Kardiol. 2019;18(2):81-85 | DOI: 10.36290/kar.2019.024

Regression of coronary atherosclerosis in light of recent studies

Tomáš Kovárník1, Karel Kopřiva2
1 II. interní klinika kardiologie a angiologie VFN a 1. LF UK v Praze
2 Kardiologické oddělení Nemocnice Na Homolce, Praha

The authors review the current knowledge on the regression of coronary atherosclerosis. The article deals with the technical aspects
of detecting coronary atherosclerosis and its changes. The authors also focus on how it is possible to manage the development
of atherosclerosis pharmacologically and, in some cases, nonpharmacologically.

Keywords: coronary atherosclerosis, intravascular ultrasound, statins, PCSK9 inhibitors

Published: May 2, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kovárník T, Kopřiva K. Regression of coronary atherosclerosis in light of recent studies. Interv Akut Kardiol. 2019;18(2):81-85. doi: 10.36290/kar.2019.024.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. JACC 2005; 46: 1225-1228. Go to original source... Go to PubMed...
    2. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and histological classification of atherosclerosis: a report from the Comitee on Vascular Lesions of the Council of Arteriosclerosis, American Heart Association. Circulation 1995; 92: 1355-1374. Go to original source... Go to PubMed...
    3. Kovarnik T, Chen Z, Wahle A, et al. Pathologic Intimal Thickening Plaque Phenotype - not as innocent as we thought. A Serial 3D Intravascular ultrasound - Virtual Histology Study. Revista Espanola de Cardiologia 2017; 70: 25-33. Go to original source... Go to PubMed...
    4. Libby P, Pasterkamp G. Requiem for the 'vulnerable plaque'. European Heart Journal 2015; 36: 2984-2987. Go to original source... Go to PubMed...
    5. Ball P. Physics of life: The dawn of quantum biology. Nature 2011; 474: 272-274. Go to original source... Go to PubMed...
    6. Kitzlerová E, Anders M. Deprese a kardiovaskulární choroby - společný průnik na rovině psychosociální a behaviorální. Čes a slov. Psychiat. 2010; 106: 87-92.
    7. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 2006; 295: 1556-1565. Go to original source... Go to PubMed...
    8. Nicholls S, Ballantyne Ch, Barter P, et al. Effect of Two Intensive Statin Regimens on Progression of Coronary Disease. NEJM 2011; 365: 2078-2087. Go to original source... Go to PubMed...
    9. Otagiri K, Tsutsui H, Kumazaki S, et al. Early Intervention With Rosuvastatin Decreases the Lipid Components of the Plaque in Acute Coronary Syndrome. Circ J. 2011; 75: 633-641. Go to original source... Go to PubMed...
    10. Kovarnik T, Mintz GS, Skalicka H, et al. Virtual histology evaluation of atherosclerosis regression during aterovastatin and ezetimibe administration. Circ J. 2012; 76: 176-183. Go to original source... Go to PubMed...
    11. Hougaard M, Hansen HS, Thayssen P, et al. Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovasc Revasc Med. 2017; 18: 110-111. Go to original source... Go to PubMed...
    12. Tsujita K, Sugiyama S, Sumida H, et al. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention The Multicenter Randomized Controlled PRECISE-IVUS Trial. JACC 2015; 66: 495-507. Go to original source... Go to PubMed...
    13. Cannon Ch, Blazing M, Giugliano R, et al. for the IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. NEJM 2015; 372: 2387-2397. Go to original source... Go to PubMed...
    14. Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, et al. PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study. Atherosclerosis 2016; 248: 117-122. Go to original source... Go to PubMed...
    15. Nicholls S, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA 2016; 316: 2373-2384. Go to original source... Go to PubMed...
    16. Puri R, Nissen SE, Ballantyne Ch, et al. Factors underlying regression of coronary atheroma with potent statin therapy. EHJ 2013; 34: 1818-1825. Go to original source... Go to PubMed...
    17. Hara T, Fukuda D, Tanaka K et al. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. Atherosclerosis 2015; 242: 639-646. Go to original source... Go to PubMed...
    18. Posthuma JJ, Posma JJ, van Oerle R, et al. Targeting Coagulation Factor Xa promotes Regression of Advanced Atherosclerosis in Apolipoprotein-e Deficient Mice. Sci Rep. 2019; 9: 3909. Go to original source... Go to PubMed...
    19. Burke AP, Kolodgie FD, Farb A, et al. Healed Plaque Ruptures and Sudden Coronary Death Evidence That Subclinical Rupture Has a Role in Plaque Progression Circulation 2001; 103: 934 - 940. Go to original source... Go to PubMed...
    20. Virmani R, Kolodgie FD, Burke AP, et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005; 25: 2054-2061. Go to original source... Go to PubMed...
    21. Perrotta P, Veseli BE, Van der Veken B. Pharmacological strategies to inhibit intra-plaque angiogenesis in atherosclerosis. Vascular Pharmacology 2018 in přes. Go to original source...
    22. Garcia-Garcia H, Gogas B, Serruys PW, Bruining N. IVUS-based imaging modalities for tissue cgaracterization: similarities and differences. In J Cardiovasc Imaging 2011; 27: 215-224. Go to original source... Go to PubMed...
    23. Nair A, Margolis P, Kuban B, Vince G, et al. Automated coronary plaque characterisation with intravascular ultrasound backscatter: ex vivo validation. Eurointervention 2007; 3: 113-120. Go to PubMed...
    24. Waxman S, Ishibashi F, Caplan JD. Rationale and use of near-infrared spectroscopy for detection of lipid-rich and vulnerable plaques. Journal of Nuclear Cardiology 2007; 14: 719-728. Go to original source... Go to PubMed...
    25. Kini AS, Baber U, Kovacic JC, et al. Changes in plaque lipid content after short-term intensive versusu standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). JACC 2013; 62: 21-29. Go to original source... Go to PubMed...
    26. Tearney G, Regar E, Akasaka T, et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies. JACC 2012; 59: 1058-1072. Go to original source... Go to PubMed...
    27. Hattori K, Ozaki Y, Ismail T, et al. Impact of Statin Therapy on Plaque Characteristics as Assessed by Serial OCT, Grayscale and Integrated Backscatter-IVUS. JACC CVI 2012; 5: 169-177. Go to original source... Go to PubMed...
    28. Kataoka Y, Andrews J, Puri R, et al. Lipid lowering therapy to modify plaque microstructures. Insights from optical coherency tomography imaging. J Atheroscler Thromb. 2017; 24: 360-72. Go to original source... Go to PubMed...
    29. Endo H, Dohi T, Miyauchi K, et al. Clinical significance of non-culprit plaque regression following acute coronary syndrome: A serial intravascular ultrasound study Journal of Cardiology 2019 in press. Go to original source... Go to PubMed...
    30. Ndrepepa G, Iijima R, Kufner S, et al. Association of progression or regression of coronary artery atherosclerosis with long-term prognosis. Am Heart J 2016; 177: 9-16. Go to original source... Go to PubMed...
    31. Sabatine M, Giugliano R, Keech A, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. NEJM 2017; 376: 1713-1722. Go to original source... Go to PubMed...
    32. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. NEJM 2018; 379: 2097-2107. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.